开发一种预警模型,用于预测卡佩西塔诱导的腹
Zhijun Liu1,2, Shi Qiu1,2, Yuan Xu3
1Research and Development Center of Chinese Medicine Resources and Biotechnology, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Drug design, development and therapy
|June 12, 2025
概括
现在可以使用一种新的早期预警模型预测capecitabine诱导的腹,这是一个常见的副作用. 该模型分析结肠组织以识别有风险的患者,改善结肠直肠癌治疗.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 腹是capecitabine (Cap) 的主要副作用,经常导致结肠直肠癌 (CRC) 患者停止治疗.
- 预测和缓解Cap诱导的腹对于维持治疗坚持和改善患者的治疗结果至关重要.
研究的目的:
- 构建和验证一个早期预警模型来预测capecitabine诱导的腹.
- 在结肠组织中识别关键的生物标志物,与capecitabine诱导的腹相关.
主要方法:
- 建立了一个capecitabine诱导的腹小鼠模型,以将药物和代谢物暴露水平与腹发病率相关联.
- 在62名结肠直肠癌患者的结肠组织中量化了代谢酶和药物载体的度.
- 使用患者数据开发了一种二进制后勤回归模型,以预测腹风险.
主要成果:
- 在小鼠中,与对照组相比,在腹阳性小鼠的结肠中观察到较高的capecitabine和某些代谢物的暴露水平.
- 在腹阳性和腹阴性CRC患者之间发现了结肠代谢酶和药物载体的表达水平的明显差异.
- 一个整合细胞二烯酸脱氨酶 (CDA) 和溶解物载体家族22成员7 (SLC22A7) 的预测模型在预测CRC患者的Cap诱导腹方面表现出高准确性 (AUC0.907).
结论:
- 一个创新的早期预警模型,用于皮胺诱导的腹已经成功开发和验证.
- 这种基于正常结肠组织中的代谢酶和药物载体的模型,为CRC治疗中个性化capecitabine剂量提供了一种新的方法.
- 这些发现为优化结直肠癌治疗提供了潜在的基础,通过预测和管理与capecitabine相关的副作用.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
111
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153